103 research outputs found
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later
In March 2005, the Remission in Schizophrenia Working Group (RSWG) proposed a consensus definition of symptomatic remission in schizophrenia and developed specific operational criteria for its assessment. They pointed out, however, that the validity and the relationship to other outcome dimensions required further examination. This article reviews studies on the validity, frequency, and predictors of symptomatic remission in schizophrenia and studies on patients' perspectives. These studies have demonstrated that the RSWG remission criteria appear achievable and sustainable for a significant proportion of patients, and are related to a better overall symptomatic status and functional outcome and, to a less clear extent, to a better quality of life and cognitive performance. However, achieving symptomatic remission is not automatically concurrent with an adequate status in other outcome dimensions. The results of the present review suggest that the RSWG remission criteria are valid and useful. As such, they should be consistently applied in clinical trials. However, the lack of consensus definitions of functional remission and adequate quality of life hampers research on their predictive validity on these outcome dimensions. Future research should therefore search for criteria of these dimensions and test whether the RSWG remission criteria consistently predict a âgoodâ outcome with respect to functioning and quality of life
Efficacy and safety of once-monthly Risperidone ISM Âź in schizophrenic patients with an acute exacerbation
Funding: This study was funded by Laboratorios FarmacĂ©uticos Rovi, S.A. Madrid, Spain. It was supported also in part by a grant from Center for the Development of Industrial Technology (Expedient No. IDI-20160109).To evaluate the efficacy and safety of Risperidone ISM Âź against placebo in patients with acute exacerbation of schizophrenia. A multicenter, randomized, double-blind, placebo-controlled study was conducted between June 2017 and December 2018 (NCT03160521). Eligible patients received once-monthly intramuscular injections of Risperidone ISM Âź (75 or 100 mg) or placebo for 12 weeks. The primary efficacy outcome was change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to week 12. The key secondary efficacy outcome was change from baseline in Clinical Global Impressions-Severity of Illness scale (CGI-S) score. Altogether, 438 patients were randomized (1:1:1) and 390 included in the modified ITT efficacy set. The PANSS total score (mean difference, 95% CI) improved significantly from baseline to day 85 with Risperidone ISM Âź 75 and 100 mg, with placebo-adjusted differences of â13.0 (95% CI, â17.3 to â8.8); (p < 0.0001), and â13.3 (â17.6 to â8.9); (p < 0.0001), respectively. Significantly improved mean changes were also obtained for CGI-S score from baseline to day 85 for both doses of Risperidone ISM Âź compared with placebo â0.7 (â1.0 to â0.5); p < 0.0001, for both doses. The statistically significant improvement for both efficacy outcomes were observed as early as 8 days after first injection. The most frequently reported treatment-emergent adverse events were increased blood prolactin (7.8%), headache (7.3%), hyperprolactinemia (5%), and weight increase (4.8%). Neither new nor unexpected relevant safety information was recorded. Risperidone ISM Âź provided rapid and progressive reduction of symptoms in patients with acutely exacerbated schizophrenia without need of oral risperidone supplementation or loading doses. Both doses were safe and well tolerated
Pulmonary and intranasal delivery of thymoquinone-loaded nanoparticles for Mucormycosis & Covid-19
India is currently reporting a massive increase of mucormycosis infection among Covid-19 patients. The opportunistic black fungus infection affects the lungs and the brain. Depending on the infected organs, morbidity and mortality rates are between 50% and 100%. To save patientsâ life, it is frequently necessary to remove jaws and eyes. The drug of first of choice for the treatment of mucormycosis in the subcontinent is Amphotericin B. There are two problems with Amphotericin B: First, it is currently not available in many pharmacies in India, and second, its effect is restricted by its limited passage across the blood-brain-barrier. Recently, it was shown that thymol is highly effective against Rhizopus oryzea, the fungus causing 70% of mucormycosis. In contrast to Amphotericin B, which in the case of mucormycosis is administered intravenously, thymol can reach the lungs via inhalation and the brain via the nose-to-brain route. Importantly, thymoquinone (TQ) has all the relevant biological properties of thymol and has been already successfully used to treat Covid-19, as demonstrated in clinical studies. Additionally to the action spectrum of thymol, TQ has the capacity to act as a reactive oxygen species and oxidize pathogens upon contact, thereby recommending itself for both treatment of Covid-19 and infections with the black fungus. For maximum efficacy, comprising biodistribution and bioavailability and drug, functionality we describe innovative strategies based on nanomedicines for targeted delivery of TQ to the lungs as well as for intranasal delivery to the brain, bypassing the blood-brain-barrier
The interrelation of needs and quality of life in first-episode schizophrenia
The interrelation between needs for care and quality of life has been described and replicated by several studies. The present work aims to add to the understanding of longitudinal interrelations between needs for care, quality of life, and other outcome measures by analyzing a sample of patients at the onset of schizophrenia. This study relied on data from the EUFEST trial, designed to compare first- and second-generation antipsychotics during 1year. At baseline, 498 patients have been included. The first (baseline) and the last assessment (12months after baseline) were used for the analyses. Predictors of quality of life were determined using regression analyses. We tested the complex longitudinal interrelations between baseline and outcome measures with structural equation models. Unmet needs were not definitively confirmed as a predictor of subsequent quality of life, unless unmet needs changing to no needs were separated from unmet needs changing to met needs. Each unmet need that changed to no need enhanced the quality of life (mean score 1-7) by 0.136 scale points. This study suggests that when studying quality of life and needs for treatment, it is crucial to differentiate whether unmet needs disappeared or whether they were met, as the former has a stronger impact on quality of lif
Anticonvulsants in the treatment of aggression in the demented elderly: an update
Complex psychopathological and behavioral symptoms, such as delusions and aggression against care providers, are often the primary cause of acute hospital admissions of elderly patients to emergency units and psychiatric departments. This issue resembles an interdisciplinary clinically highly relevant diagnostic and therapeutic challenge across many medical subjects and general practice. At least 50% of the dramatically growing number of patients with dementia exerts aggressive and agitated symptoms during the course of clinical progression, particularly at moderate clinical severity. METHODS: Commonly used rating scales for agitation and aggression are reviewed and discussed. Furthermore, we focus in this article on benefits and limitations of all available data of anticonvulsants published in this specific indication, such as valproate, carbamazepine, oxcarbazepine, lamotrigine, gabapentin and topiramate. RESULTS: To date, most positive and robust data are available for carbamazepine, however, pharmacokinetic interactions with secondary enzyme induction limit its use. Controlled data of valproate do not seem to support the use in this population. For oxcarbazepine only one controlled but negative trial is available. Positive small series and case reports have been reported for lamotrigine, gabapentin and topiramate. CONCLUSION: So far, data of anticonvulsants in demented patients with behavioral disturbances are not convincing. Controlled clinical trials using specific, valid and psychometrically sound instruments of newer anticonvulsants with a better tolerability profile are mandatory to verify whether they can contribute as treatment option in this indication
Early onset of treatment effects with oral risperidone
BACKGROUND: The dogma of a delayed onset of antipsychotic treatment effects has been maintained over the past decades. However, recent studies have challenged this concept. We therefore performed an analysis of the onset of antipsychotic treatment effects in a sample of acutely decompensated patients with schizophrenia. METHODS: In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone. PANSS-ratings were obtained on day 0, day 1, day 3, day 7 and day 14. RESULTS: Significant effects of treatment were already present on day 1 and continued throughout the study. The PANSS positive subscore and the PANSS total score improved significantly more than the PANSS negative subscore. CONCLUSION: Our results are consistent with the growing number of studies suggesting an early onset of antipsychotic treatment effects. However, non-pharmacological effects of treatment also need to be taken into consideration
- âŠ